CA3198309A1 - Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same - Google Patents

Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same

Info

Publication number
CA3198309A1
CA3198309A1 CA3198309A CA3198309A CA3198309A1 CA 3198309 A1 CA3198309 A1 CA 3198309A1 CA 3198309 A CA3198309 A CA 3198309A CA 3198309 A CA3198309 A CA 3198309A CA 3198309 A1 CA3198309 A1 CA 3198309A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
formulation
substantially free
anions
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198309A
Other languages
English (en)
French (fr)
Inventor
Heinrich Haas
Kaushik THANKI
Isaac Hernan ESPARZA BORQUEZ
Sebastian Horner
Bulat SYDYKOV
Martin Kapp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of CA3198309A1 publication Critical patent/CA3198309A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3198309A 2020-11-16 2021-11-15 Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same Pending CA3198309A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063114478P 2020-11-16 2020-11-16
US63/114,478 2020-11-16
EP2020082602 2020-11-18
EPPCT/EP2020/082602 2020-11-18
PCT/EP2021/081741 WO2022101486A1 (en) 2020-11-16 2021-11-15 Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same

Publications (1)

Publication Number Publication Date
CA3198309A1 true CA3198309A1 (en) 2022-05-19

Family

ID=78617419

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198309A Pending CA3198309A1 (en) 2020-11-16 2021-11-15 Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same

Country Status (6)

Country Link
US (1) US20240033344A1 (enExample)
EP (1) EP4243787A1 (enExample)
JP (1) JP2023552678A (enExample)
AU (1) AU2021377746A1 (enExample)
CA (1) CA3198309A1 (enExample)
WO (2) WO2022101486A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524023B2 (en) * 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN114989182B (zh) * 2022-06-23 2023-06-23 尧唐(上海)生物科技有限公司 脂质化合物、包含其的组合物及应用
WO2024006863A1 (en) * 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN115869394A (zh) * 2022-07-21 2023-03-31 中国食品药品检定研究院 核酸佐剂、含有所述核酸佐剂的疫苗及应用
AU2023408183A1 (en) * 2022-12-23 2025-07-10 Eli Lilly And Company Stabilization of lipid nanoparticle formulations
WO2024160829A1 (en) 2023-01-31 2024-08-08 BioNTech SE Compositions and methods
US11833224B1 (en) * 2023-02-08 2023-12-05 Leuvian Llc Lyoprotectant compositions and uses thereof
WO2024184500A1 (en) * 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024193827A1 (en) * 2023-03-23 2024-09-26 BioNTech SE Stabilized nucleic acid compositions and methods for preparing, storing and using the same
EP4442256A1 (en) * 2023-04-04 2024-10-09 Københavns Universitet Lipid nanoparticle compositions
TW202446402A (zh) * 2023-04-12 2024-12-01 美商艾拉倫製藥公司 用於寡核苷酸遞送之調配物
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
AU2023457883A1 (en) * 2023-06-28 2025-12-18 Global Life Sciences Solutions Canada Ulc Lipid nanoparticle formulations for cell therapy and related methods
WO2025040724A1 (en) * 2023-08-21 2025-02-27 Global Life Sciences Solutions Canada Ulc Method and apparatus for ion flux lipid nanoparticle manufacture
WO2025061153A1 (en) * 2023-09-22 2025-03-27 Everest Medicines (China) Co., Ltd. Rna-lipid particles comprising polysarcosine-lipid conjugate
WO2025087303A1 (en) * 2023-10-24 2025-05-01 Mote Therapeutics Inc. Lipid nanoparticle with non-covalent bifunctional binders for active targeting
WO2025133105A1 (en) * 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Compositions and methods
WO2025176732A1 (en) 2024-02-20 2025-08-28 BioNTech SE Compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
BR112016009014B1 (pt) * 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
CA2984125A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
IL307179A (en) * 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
ES2900272T3 (es) 2016-04-22 2022-03-16 BioNTech SE Métodos para proporcionar ARN monocatenario
CA3027201A1 (en) * 2016-06-14 2017-12-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2017350488B2 (en) 2016-10-26 2022-06-23 Acuitas Therapeutics Inc. Lipid nanoparticle mRNA vaccines
IL317488A (en) * 2018-10-02 2025-02-01 Intellia Therapeutics Inc Ionizable lipid amines

Also Published As

Publication number Publication date
AU2021377746A9 (en) 2024-09-26
WO2022101471A1 (en) 2022-05-19
AU2021377746A1 (en) 2023-06-08
US20240033344A1 (en) 2024-02-01
JP2023552678A (ja) 2023-12-19
WO2022101486A1 (en) 2022-05-19
EP4243787A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
CA3198309A1 (en) Pharmaceutical compositions comprising particles and mrna and methods for preparing and storing the same
US20230414747A1 (en) Lnp compositions comprising rna and methods for preparing, storing and using the same
AU2022336160B2 (en) Potency assay for therapeutic potential of coding nucleic acid
US20240408032A1 (en) Lipid-based rna formulations suitable for therapy
AU2022426637A1 (en) Lipid-based formulations for administration of rna
WO2022218503A1 (en) Lnp compositions comprising rna and methods for preparing, storing and using the same
US20250222132A1 (en) Nucleic acid compositions comprising a multivalent anion, such as an inorganic polyphosphate, and methods for preparing, storing and using the same
US20240226132A1 (en) Rna compositions comprising a buffer substance and methods for preparing, storing and using the same
CN116669709A (zh) 包含颗粒和mRNA的药物组合物及其制备和储存的方法
WO2024180363A1 (en) Linker sequence potency assays for multiple coding nucleic acids
WO2024180054A1 (en) Linker sequence potency assays for multiple coding nucleic acids